StreetInsider.com News Articles

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Graves Adrienne L

Fri, 12 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26642149.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Graves Adrienne L

Fri, 12 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26642149.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Warden Charles M

Fri, 12 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26642154.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Warden Charles M

Fri, 12 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26642154.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Robins Jason Shand

Fri, 12 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260612/26642145.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Robins Jason Shand

Fri, 12 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260612/26642145.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: LINDSTROM RICHARD L MD

Fri, 12 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260612/26642127.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: LINDSTROM RICHARD L MD

Fri, 12 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260612/26642127.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Hong Seung Suh

Fri, 12 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260612/26642136.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Hong Seung Suh

Fri, 12 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260612/26642136.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: RAINES MERILEE

Fri, 12 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260612/26642114.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: RAINES MERILEE

Fri, 12 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260612/26642114.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Williams Leslie J.

Fri, 12 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260612/26642108.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 10 Filed by: Williams Leslie J.

Fri, 12 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260612/26642108.html

Form 8-K OCULAR THERAPEUTIX, INC For: Jun 10

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641202.html

Form 8-K OCULAR THERAPEUTIX, INC For: Jun 10

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641202.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 03 Filed by: Waheed Nadia

Fri, 05 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26610877.html

Form 4 OCULAR THERAPEUTIX, INC For: Jun 03 Filed by: Waheed Nadia

Fri, 05 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260605/26610877.html

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 05 Jun 2026 07:00:00 -0400

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to seven newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 05 Jun 2026 07:00:00 -0400

The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 05 Jun 2026 07:00:00 -0400

The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 05 Jun 2026 07:00:00 -0400

The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Thu, 04 Jun 2026 07:00:00 -0400

BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Clinical Trials at the Summit (CTS) 2026 Presentation Details:

Fireside Chat with Wiley Chambers, MD
Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer

Presentation Title: OTX-TKI: Overview of Science
Session: Clinical Trials Addressing nAMD,

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Thu, 04 Jun 2026 07:00:00 -0400

Clinical Trials at the Summit (CTS) 2026 Presentation Details:

Fireside Chat with Wiley Chambers, MD
Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer

Presentation Title: OTX-TKI: Overview of Science
Session: Clinical Trials Addressing nAMD,

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Thu, 04 Jun 2026 07:00:00 -0400

Clinical Trials at the Summit (CTS) 2026 Presentation Details:

Fireside Chat with Wiley Chambers, MD
Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer

Presentation Title: OTX-TKI: Overview of Science
Session: Clinical Trials Addressing nAMD,